Semaglutide Semaglutide has been developed based on the vast body of research behind the development of liraglutide ( N -[8-(2-hydroxybenzoyl) aminocaprylate] or SNAC), which, when co-administered with semaglutide, was demonstrated to give therapeutic levels of the latter ( Both the subcutaneous and oral formulations of semaglutide have undergone extensive phase 3 clinical testing ( Table 1 )
Try one new food each week
[9] Important safety considerations include monitoring for signs of acute pancreatitis (severe, persistent abdominal pain, sometimes with vomiting) which requires urgent medical assessment, and potential worsening of diabetic retinopathy, particularly in patients with pre-existing retinopathy experiencing rapid improvement in blood glucose control
Trial data shows it helped people reduce their weight by 13% over 13 weeks, just a percent or two below other popular obesity drugs but on a much shorter timeline
Start at the lowest dose
However, this study specifically evaluated outcomes during the 1-year follow-up period after completion of a discreet 6-month treatment period [26]
